|Articles|March 19, 2020
Episode 52: Cannabinoids
Author(s)Christen Harm, Elaine Quilici
Yuval Cohen, CEO of Corbus Pharmaceuticals, talks about cannabinoids, the differences between natural and synthetic products, and how biotechs and pharma are using them to treat disease today.
Advertisement
Yuval Cohen, CEO of Corbus Pharmaceuticals, talks about cannabinoids, the differences between natural and synthetic products, and how biotechs and pharma are using them to treat disease today.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Beyond JAK Inhibitors: Biologics Signal a New Era in Alopecia Areata
2
Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio
3
Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI
4
U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report
5